Genentech Logo
Banner Image

Alan Olivero

Alan Olivero
Alan Olivero Associate Director: Discovery Chemistry

Profile | Education/Background | Top Scientific Papers

Top Scientific Papers

  • Sutherlin DP, Sampath D, Berry M, Castanedo G, Chang Z, Chuckowree I, Dotson J, Folkes A, Friedman L, Goldsmith R, Heffron T, Lee L, Lesnick J, Lewis C, Mathieu S, Nonomiya J, Olivero A, Pang J, Prior WW, Salphati L, Sideris S, Tian Q, Tsui V, Wan NC, Wang S, Wiesmann C, Wong S, Zhu BY. Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer. J Med Chem 2010 Feb 11; 53(3): 1086-97. View Abstract on PubMed

  • Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 2008 Sep 25; 51(18): 5522-32. View Abstract on PubMed

  • Hansen JD, Grina J, Newhouse B, Welch M, Topalov G, Littman N, Callejo M, Gloor S, Martinson M, Laird E, Brandhuber BJ, Vigers G, Morales T, Woessner R, Randolph N, Lyssikatos J, Olivero A. Potent and selective pyrazole-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett 2008 Aug 15; 18(16): 4692-5. View Abstract on PubMed

  • Olivero AG, Eigenbrot C, Goldsmith R, Robarge K, Artis DR, Flygare J, Rawson T, Sutherlin DP, Kadkhodayan S, Beresini M, Elliott LO, DeGuzman GG, Banner DW, Ultsch M, Marzec U, Hanson SR, Refino C, Bunting S, Kirchhofer D. A selective, slow binding inhibitor of factor VIIa binds to a nonstandard active site conformation and attenuates thrombus formation in vivo. J Biol Chem 2005 Mar 11; 280(10): 9160-9. View Abstract on PubMed

  • Lazarus RA, Olivero AG, Eigenbrot C, Kirchhofer D. Inhibitors of Tissue Factor.Factor VIIa for anticoagulant therapy. Curr Med Chem 2004 Sep; 11(17): 2275-90. View Abstract on PubMed

  • Robarge KD, Dina MS, Somers TC, Lee A, Rawson TE, Olivero AG, Tischler MH, Webb RR 2nd, Weese KJ, Aliagas I, Blackburn BK. Preparation and biological activity of novel tricyclic GPIIb/IIIa antagonists. Bioorg Med Chem 1998 Dec; 6(12): 2345-81. View Abstract on PubMed

  • Shahrokh Z, Lee E, Olivero AG, Matamoros RA, Robarge KD, Lee A, Weise KJ, Blackburn BK, Powell MF. Stability of alkoxycarbonylamidine prodrugs. Pharm Res 1998 Mar; 15(3): 434-41. View Abstract on PubMed

  • Blackburn BK, Lee A, Baier M, Kohl B, Olivero AG, Matamoros R, Robarge KD, McDowell RS. From peptide to non-peptide. 3. Atropisomeric GPIIbIIIa antagonists containing the 3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione nucleus. J Med Chem 1997 Feb 28; 40(5): 717-29. View Abstract on PubMed